Microbot Medical Inc.
For the period ended Dec 31, 2025. Filed Mar 26, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 26, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Except as described below, during the three months ended December 31, 2025, no director or officer, as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
On December 10, 2025, Simon Sharon, our Chief Technology Officer and General Manager, Microbot Israel, adopted a Rule 10b5-1 trading arrangement with the intention to satisfy the affirmative defense of Rule 10b5-1(c). The trading arrangement is for a term of two years, and is for a total of 185,888 shares of the Company’s common stock that Mr. Sharon may acquire through the exercise of outstanding stock options owned by him.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.